Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.57 Consensus PT from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $16.57.

A number of research firms have recently weighed in on YMAB. HC Wainwright increased their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target (up from $12.00) on shares of Y-mAbs Therapeutics in a research report on Monday, February 12th. Canaccord Genuity Group raised their target price on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, BMO Capital Markets boosted their price target on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock opened at $17.21 on Friday. The business’s 50-day simple moving average is $15.74 and its two-hundred day simple moving average is $11.13. The company has a market cap of $755.00 million, a PE ratio of -35.12 and a beta of 0.78. Y-mAbs Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. The firm had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. As a group, analysts predict that Y-mAbs Therapeutics will post -0.43 EPS for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the transaction, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 21.50% of the stock is owned by company insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter worth approximately $100,000. Strs Ohio grew its holdings in shares of Y-mAbs Therapeutics by 20.1% during the third quarter. Strs Ohio now owns 89,000 shares of the company’s stock worth $485,000 after buying an additional 14,900 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Y-mAbs Therapeutics by 20.1% in the third quarter. Victory Capital Management Inc. now owns 109,500 shares of the company’s stock valued at $597,000 after buying an additional 18,320 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of Y-mAbs Therapeutics by 12.2% in the third quarter. Los Angeles Capital Management LLC now owns 303,920 shares of the company’s stock worth $1,656,000 after buying an additional 32,994 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Y-mAbs Therapeutics by 258.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company’s stock worth $448,000 after acquiring an additional 59,201 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.